"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 2 | 2 | 4 |
| 2000 | 2 | 2 | 4 |
| 2002 | 5 | 1 | 6 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 5 | 7 |
| 2006 | 5 | 2 | 7 |
| 2007 | 4 | 2 | 6 |
| 2008 | 6 | 8 | 14 |
| 2009 | 4 | 1 | 5 |
| 2010 | 2 | 2 | 4 |
| 2011 | 10 | 4 | 14 |
| 2012 | 3 | 5 | 8 |
| 2013 | 9 | 4 | 13 |
| 2014 | 13 | 9 | 22 |
| 2015 | 10 | 4 | 14 |
| 2016 | 7 | 2 | 9 |
| 2017 | 9 | 2 | 11 |
| 2018 | 10 | 6 | 16 |
| 2019 | 4 | 6 | 10 |
| 2020 | 9 | 3 | 12 |
| 2021 | 4 | 4 | 8 |
| 2022 | 2 | 2 | 4 |
| 2023 | 1 | 10 | 11 |
| 2024 | 6 | 2 | 8 |
| 2025 | 5 | 6 | 11 |
| 2026 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia. Hematol Oncol. 2026 May; 44(3):e70198.
-
Potassium-competitive acid blockers for erosive reflux disease and stress ulcer prophylaxis: a narrative review. Pol Arch Intern Med. 2026 06 25; 136(6).
-
Updates on Use and Monitoring of Direct Thrombin Inhibitors. Clin Lab Med. 2026 Jun; 46(2):259-277.
-
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenstr?m Macroglobulinemia. Am J Hematol. 2026 Jun; 101(6):1255-1263.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.
-
Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV. J Control Release. 2026 02 10; 390:114559.
-
Efficacy of fourteen-day once-daily vonoprazan-based quadruple therapy for Helicobacter pylori in high clarithromycin-resistance regions (ONCE-VONO Trial). Sci Rep. 2025 12 18; 15(1):44105.
-
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood. 2025 Nov 20; 146(21):2608-2611.
-
BCL-2 inhibition in Waldenstr?m macroglobulinaemia and marginal zone lymphoma. Br J Haematol. 2025 Dec; 207(6):2261-2269.
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr?m macroglobulinemia. Blood Adv. 2025 Oct 14; 9(19):4842-4847.